BGB601

BGB601 (ADCT-601) is an antibody drug conjugate (ADC) composed of a humanised IgG1 antibody against human AXL that is linked to a cytotoxin. In pre-clinical experiments, BGB601 demonstrated potent and specific in vitro and in vivo anti-tumour activity in various cancer-derived models with different levels of membranous AXL. BGB601 is out-licensed to ADC Therapeutics S.a.r.l.

Primary Sidebar

News Subscription

Please remember to confirm your email by clicking on the link provided in the subscription confirmation email.

We will save your name and email address with the sole purpose of sending information regarding our latest news and events. By subscribing to BerGenBio’s newsletter you consent to our Privacy Policy and Terms of Use.